For U.S. Residents Only
Logo
stay connected

Living with aTTP/iTTP*

Heather, real patient. Individual results may vary.
Heather is being compensated by Sanofi.

While some people may only experience one aTTP/iTTP episode, others may experience a relapse

An aTTP/iTTP episode is an acute episode. This means it happens suddenly and lasts for a short time with treatment. However, some patients who had one aTTP/iTTP episode may have another.

A study of the medical records of 21 people with aTTP/iTTP over 30 years showed that 90% experienced another episode over their lifetime. This is called a relapse.

*aTTP is also known as iTTP. The terms can be used interchangeably.

It is important to be aware of and watch for any aTTP/iTTP symptoms. If you think that you have signs and symptoms of an aTTP/iTTP episode, talk to your doctor or visit your local emergency room right away.

Symptoms can include:

  • Bleeding from the gums or nose
  • Purple bruises (known as purpura) and/or red or purple dots (known as petechiae) on the skin
  • Blood in urine
  • Stomach pain
  • Chest pain
  • Seizures
  • Headaches, confusion, or distorted vision
  • Tiredness and jaundice (yellowing of the skin and eyes)

Sign up to receive helpful information and resources

Stay connected

Alex, real patient. Individual results may vary.
Alex is being compensated by Sanofi.

CABLIVI can help make a difference

See how CABLIVI may help you
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Who should not take CABLIVI?

Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?
Add
IMPORTANT SAFETY INFORMATION AND INDICATIONS
What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Who should not take CABLIVI?

Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.

Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.

You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.

CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.

The most common side effects include nosebleed, headache and bleeding gums.

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

Please see full Prescribing Information
Instructions for Use
Sharps Medical Waste Disposal (PDF)

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.